Stock Research for MEIP

MEIP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MEIP Stock Chart & Research Data

The MEIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MEIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MEIP Due diligence Resources & Stock Charts

The MEIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MEIP Detailed Price Forecast - CNN Money CNN View MEIP Detailed Summary - Google Finance
Yahoo View MEIP Detailed Summary - Yahoo! Finance Zacks View MEIP Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View MEIP Trends & Analysis - Trade-Ideas Barrons View MEIP Major Holders - Barrons
NASDAQ View MEIP Call Transcripts - NASDAQ Seeking View MEIP Breaking News & Analysis - Seeking Alpha
Spotlight View MEIP Annual Report - CompanySpotlight.com OTC Report View MEIP OTC Short Report - OTCShortReport.com
TradeKing View MEIP Fundamentals - TradeKing Charts View MEIP SEC Filings - Bar Chart
WSJ View Historical Prices for MEIP - The WSJ Morningstar View Performance/Total Return for MEIP - Morningstar
MarketWatch View the Analyst Estimates for MEIP - MarketWatch CNBC View the Earnings History for MEIP - CNBC
StockMarketWatch View the MEIP Earnings - StockMarketWatch MacroAxis View MEIP Buy or Sell Recommendations - MacroAxis
Bullish View the MEIP Bullish Patterns - American Bulls Short Pains View MEIP Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View MEIP Stock Mentions - StockTwits PennyStocks View MEIP Stock Mentions - PennyStockTweets
Twitter View MEIP Stock Mentions - Twitter Invest Hub View MEIP Investment Forum News - Investor Hub
Yahoo View MEIP Stock Mentions - Yahoo! Message Board Seeking Alpha View MEIP Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for MEIP - SECform4.com Insider Cow View Insider Transactions for MEIP - Insider Cow
CNBC View MEIP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MEIP - OTC Markets
Yahoo View Insider Transactions for MEIP - Yahoo! Finance NASDAQ View Institutional Holdings for MEIP - NASDAQ


Stock Charts

FinViz View MEIP Stock Insight & Charts - FinViz.com StockCharts View MEIP Investment Charts - StockCharts.com
BarChart View MEIP Stock Overview & Charts - BarChart Trading View View MEIP User Generated Charts - Trading View


Latest Financial News for MEIP

MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Posted on Friday June 15, 2018

SAN DIEGO, June 15, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP) a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announced that results from a Phase 1b study of ME-401 in patients with relapsed or refractory follicular lymphoma (FL), chronic lymphocytic lymphoma (CLL) and small lymphocytic lymphoma (SLL) are being presented during a poster presentation today, Friday, June 15, 2018 at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden. Complete data results on the Phase 1b study were previously announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in June 2018.


MEI Pharma, Partnerships, Well-Funded Clinical Programs and Promising Clinical Data Driving Oncology Research
Posted on Monday June 11, 2018

Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MEI Pharma (MEIP), a San Diego-based oncology drug development company with a pipeline of three clinical-stage drug candidates and oncology drug development experience. Followed by promising partnerships, well-funded clinical programs, and most recently, promising data at ASCO for ME-401 and the potential for having a best-in-class P13K Delta oral inhibitor. On June 4th, the company announced that data presented at ASCO 2018 from a Phase 1b study of ME-401, demonstrated a 90% objective response rate in patients with relapsed or refractory follicular lymphoma (FL), chronic lymphocytic lymphoma (CLL) and small lymphocytic lymphoma (SLL).


MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Posted on Monday June 04, 2018

-- 90% Objective Response Rate Observed in Patients with Indolent B-Cell Malignancies -- SAN DIEGO , June 4, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) a pharmaceutical company focused on leveraging ...


MEI Pharma Presents Clinical Data for ME-344 in HER2 Negative Breast Cancer Patients at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Posted on Monday June 04, 2018

SAN DIEGO, June 4, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announced that data presented at ASCO 2018 from an investigator-initiated study of ME-344 in patients with HER2 negative breast cancer demonstrate evidence of inhibition of tumor proliferation as measured by Ki-67 reductions.


Enter a stock symbol to view the stock details.